Tyra Biosciences, Inc. (TYRA) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Tyra Biosciences, Inc. is a clinical-stage biotechnology company developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology. The company utilizes its proprietary SNÅP platform to design therapies for targeted oncology and genetically defined conditions. This report covers the quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(18.7) million | $(36.9) million | $(25.2) million |
| Operating Expenses | $23.5 million | $45.9 million | $30.3 million |
| Interest & Other Income | $4.8 million | $9.0 million | $5.2 million |
| Cash & Marketable Securities | $373.8 million (as of June 30, 2024) | ||
| Accumulated Deficit | $(201.7) million (as of June 30, 2024) | ||
| Net Cash Used in Operating Activities | N/A | $(32.3) million | $(19.5) million |
Material Changes vs. Prior Period
- Capital Raise: In February 2024, the company completed a private placement raising approximately $200 million in gross proceeds through the issuance of common stock and pre-funded warrants. This significantly increased cash and marketable securities from $204.5 million at year-end 2023 to $373.8 million at June 30, 2024.
- Expense Growth: Operating expenses increased by $15.5 million (51%) for the six months ended June 30, 2024, compared to the same period in 2023.
- R&D Expenses: Rose $12.6 million to $35.2 million, driven by increased CRO and drug manufacturing costs ($7.6 million) and personnel costs ($2.4 million) to support clinical trials for TYRA-300 and TYRA-200.
- G&A Expenses: Rose $2.9 million to $10.7 million, primarily due to higher stock-based compensation ($1.4 million) and professional service costs.
- Interest Income: Other income increased by $3.8 million year-over-year due to higher interest rates and increased cash balances from the private placement.
Outlook, Management Commentary, and Risks
- Liquidity: Management believes current cash, cash equivalents, and marketable securities ($373.8 million) are sufficient to fund operations through at least 2026.
- Pipeline Updates:
- TYRA-300: Phase 1 trial (SURF301) for urothelial carcinoma is ongoing. The company plans to submit an IND application in H2 2024 for a Phase 2 trial in Achondroplasia (ACH). FDA granted Orphan Drug and Rare Pediatric Disease designations.
- TYRA-200: Phase 1 trial (SURF201) for cholangiocarcinoma is evaluating safety and dosing.
- TYRA-430: FDA allowed the IND to proceed for a Phase 1 study in hepatocellular carcinoma (HCC) in August 2024.
- Management Changes: On August 4, 2024, the company announced a transition agreement with Chief Medical Officer Hiroomi Tada, who will remain until a successor is appointed (no later than Jan 1, 2025) before transitioning to a Special Advisor role.
- Risks: The company has never generated revenue and expects to incur significant losses for the foreseeable future. Success depends on clinical trial outcomes, regulatory approvals, and the ability to raise additional capital if needed.
Key Facts for Investor Verification
- Verify the timeline and enrollment progress of the TYRA-300 Phase 1 trial and the anticipated submission date for the Achondroplasia IND.
- Monitor the burn rate relative to the $373.8 million cash position to confirm the runway through 2026 remains valid given increased R&D spending.
- Review the status of the CMO transition and the appointment of a successor to ensure continuity in clinical development.
- Assess the impact of stock-based compensation ($8.5 million YTD 2024) on future dilution and expense management.
- Confirm the regulatory status of TYRA-430 following the August 2024 FDA clearance for the Phase 1 study.